Immunate S/D (Human Coagulation Factor Viii, Human Von Willebrand Factor)

Immunate S/D is used to replace deficient clotting factors in the intrinsic coagulation pathway for bleeding disorders.

• Hemophilia A: provides factor VIII to restore clot formation and reduce bleeding episodes.
• von Willebrand disease: supplies von Willebrand factor to improve platelet adhesion and stabilize factor VIII, controlling mucosal and surgical bleeding.
• Perioperative management in hemophilia A or von Willebrand disease: achieves hemostasis during surgery or invasive procedures.

• Immunate S/D delivers exogenous human factor VIII together with von Willebrand factor directly into the bloodstream. Factor VIII participates in the intrinsic coagulation cascade, forming the tenase complex that activates factor X. Von Willebrand factor binds to platelet glycoprotein Ib, mediating platelet adhesion to subendothelial collagen and also protects factor VIII from rapid clearance, thereby enhancing clot formation and achieving hemostasis.

Adverse reactions to Immunate S/D may vary in frequency and severity.

Common Side Effects

• Fever: mild temperature elevation after infusion.
• Headache: transient cranial discomfort.
• Nausea: occasional feeling of sickness.
• Injection site pain: localized discomfort at the IV site.

Serious or Rare Side Effects

• Anaphylaxis: severe allergic reaction requiring immediate medical attention.
• Development of inhibitors: neutralizing antibodies against factor VIII that reduce efficacy.
• Thromboembolic events: formation of abnormal clots in veins or arteries.

When using Immunate S/D, several precautions should be observed to ensure safety and efficacy.

• Assess inhibitor status: test for pre‑existing antibodies against factor VIII before initiating therapy.
• Monitor for allergic reactions: observe patients during and after infusion for signs of hypersensitivity.
• Adjust dose in renal or hepatic impairment: consider individual patient factors when determining infusion volume.
• Avoid concurrent use with high‑dose pro‑coagulants: may increase risk of thrombosis.
• Pregnancy and lactation: use only if clearly needed and after risk‑benefit assessment.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Immunate S/D can interact with other medicines, affecting clotting balance or immune response.

Major Interactions (Avoid)

• Concurrent high‑dose activated pro‑coagulants (e.g., recombinant factor VIIa): may precipitate thrombotic complications.
• Antifibrinolytic agents (e.g., tranexamic acid) in excessive doses: increase risk of clot formation.

Moderate Interactions (Monitor Closely)

• Immunosuppressants (e.g., rituximab): may alter inhibitor development.
• Antibiotics that affect renal function (e.g., aminoglycosides): require monitoring of infusion tolerance.
• Vaccines administered shortly before or after infusion: may affect immune response.